Skip to content
Sign inOpen the app
Artwork for Pharmaceutical Executive
Pharmaceutical Executive · July 14 · 2 min

Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik

In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.

0:00-2:34
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.

more episodes

All episodes